These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21784416)

  • 1. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.
    LeWitt P; Schultz L; Auinger P; Lu M;
    Brain Res; 2011 Aug; 1408():88-97. PubMed ID: 21784416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
    Stefani A; Pierantozzi M; Olivola E; Galati S; Cerroni R; D'Angelo V; Hainsworth AH; Saviozzi V; Fedele E; Liguori C
    Neurochem Int; 2017 May; 105():58-63. PubMed ID: 28108196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
    Cheng FC; Kuo JS; Chia LG; Dryhurst G
    J Neural Transm (Vienna); 1996; 103(4):433-46. PubMed ID: 9617787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
    Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in CSF biomarkers for Parkinson's disease.
    LeWitt P
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S49-51. PubMed ID: 22166453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
    LeWitt PA; Galloway MP; Matson W; Milbury P; McDermott M; Srivastava DK; Oakes D
    Neurology; 1992 Nov; 42(11):2111-7. PubMed ID: 1436520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease.
    Ishibashi K; Kanemaru K; Saito Y; Murayama S; Oda K; Ishiwata K; Mizusawa H; Ishii K
    Acta Neurol Scand; 2010 Jul; 122(1):46-51. PubMed ID: 20002007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Vargas C; Gómez P; De Bustos F; Zurdo M; Gómez-Escalonilla C; Barcenilla B; Berbel A; Camacho A; Arenas J
    J Neural Transm (Vienna); 2000; 107(4):445-9. PubMed ID: 11215755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients].
    Krygowska-Wajs A; Szczudlik A; Antkiewicz-Michaluk L; Romańska I; Vetulani J
    Neurol Neurochir Pol; 1997; 31(5):875-85. PubMed ID: 9513952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease.
    Growdon JH; Melamed E; Logue M; Hefti F; Wurtman RJ
    Life Sci; 1982 Mar; 30(10):827-32. PubMed ID: 6175872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
    Prell GD; Khandelwal JK; Burns RS; Blandina P; Morrishow AM; Green JP
    J Neural Transm Park Dis Dement Sect; 1991; 3(2):109-25. PubMed ID: 1910485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Kremer T; Taylor KI; Siebourg-Polster J; Gerken T; Staempfli A; Czech C; Dukart J; Galasko D; Foroud T; Chahine LM; Coffey CS; Simuni T; Weintraub D; Seibyl J; Poston KL; Toga AW; Tanner CM; Marek K; Hutten SJ; Dziadek S; Trenkwalder C; Pagano G; Mollenhauer B
    Mov Disord; 2021 Aug; 36(8):1972-1978. PubMed ID: 33942926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia.
    Jolkkonen J; Soininen H; Halonen T; Ylinen A; Laulumaa V; Laakso M; Riekkinen P
    J Neurol Neurosurg Psychiatry; 1986 Dec; 49(12):1374-7. PubMed ID: 2433403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
    Poceta JS; Parsons L; Engelland S; Kripke DF
    Sleep Med; 2009 Jan; 10(1):129-33. PubMed ID: 18207455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
    Zubenko GS; Marquis JK; Volicer L; Direnfeld LK; Langlais PJ; Nixon RA
    Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Hernánz A; Fernández-Vivancos E; de Bustos F; Barcenilla B; Gómez-Escalonilla C; Zurdo M; Berbel A; Villanueva C
    Neurosci Lett; 1999 Aug; 271(1):33-6. PubMed ID: 10471207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased beta-phenylethylamine in CSF in Parkinson's disease.
    Zhou G; Shoji H; Yamada S; Matsuishi T
    J Neurol Neurosurg Psychiatry; 1997 Dec; 63(6):754-8. PubMed ID: 9416810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
    Weiner WJ; Klawans HL
    J Neurol Neurosurg Psychiatry; 1973 Oct; 36(5):747-52. PubMed ID: 4753871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.